Mack Volker
Senior Principal Scientist Boehringer Ingelheim
Seminars
Wednesday 28th October 2026
Identifying New Therapeutic Opportunities for Well-Tolerated & Efficacious Obesity Treatment Beyond GLP1
9:45 am
- Highlighting an attractive GLP1-independent drug discovery approach
- Profiling potent peptide agonists for convenient weight loss
- Combining complementary MoAs for well tolerated and effective anti-obesity therapy
